Cargando…
An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology
Immune-mediated diseases and immunotherapeutics can negatively affect normal immune functioning and, consequently, vaccine safety and response. The COVID-19 pandemic has incited research aimed at developing a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. As SARS-CoV-2 v...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
by the American Academy of Dermatology, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816618/ https://www.ncbi.nlm.nih.gov/pubmed/33482251 http://dx.doi.org/10.1016/j.jaad.2021.01.047 |
_version_ | 1783638480696377344 |
---|---|
author | Gresham, Louise M. Marzario, Barbara Dutz, Jan Kirchhof, Mark G. |
author_facet | Gresham, Louise M. Marzario, Barbara Dutz, Jan Kirchhof, Mark G. |
author_sort | Gresham, Louise M. |
collection | PubMed |
description | Immune-mediated diseases and immunotherapeutics can negatively affect normal immune functioning and, consequently, vaccine safety and response. The COVID-19 pandemic has incited research aimed at developing a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. As SARS-CoV-2 vaccines are developed and made available, the assessment of anticipated safety and efficacy in patients with immune-mediated dermatologic diseases and requiring immunosuppressive and/or immunomodulatory therapy is particularly important. A review of the literature was conducted by a multidisciplinary committee to provide guidance on the safety and efficacy of SARS-CoV-2 vaccination for dermatologists and other clinicians when prescribing immunotherapeutics. The vaccine platforms being used to develop SARS-CoV-2 vaccines are expected to be safe and potentially effective for dermatology patients on immunotherapeutics. Current guidelines for the vaccination of an immunocompromised host remain appropriate when considering future administration of SARS-CoV-2 vaccines. |
format | Online Article Text |
id | pubmed-7816618 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | by the American Academy of Dermatology, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78166182021-01-21 An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology Gresham, Louise M. Marzario, Barbara Dutz, Jan Kirchhof, Mark G. J Am Acad Dermatol Review Immune-mediated diseases and immunotherapeutics can negatively affect normal immune functioning and, consequently, vaccine safety and response. The COVID-19 pandemic has incited research aimed at developing a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. As SARS-CoV-2 vaccines are developed and made available, the assessment of anticipated safety and efficacy in patients with immune-mediated dermatologic diseases and requiring immunosuppressive and/or immunomodulatory therapy is particularly important. A review of the literature was conducted by a multidisciplinary committee to provide guidance on the safety and efficacy of SARS-CoV-2 vaccination for dermatologists and other clinicians when prescribing immunotherapeutics. The vaccine platforms being used to develop SARS-CoV-2 vaccines are expected to be safe and potentially effective for dermatology patients on immunotherapeutics. Current guidelines for the vaccination of an immunocompromised host remain appropriate when considering future administration of SARS-CoV-2 vaccines. by the American Academy of Dermatology, Inc. 2021-06 2021-01-19 /pmc/articles/PMC7816618/ /pubmed/33482251 http://dx.doi.org/10.1016/j.jaad.2021.01.047 Text en © 2021 by the American Academy of Dermatology, Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Gresham, Louise M. Marzario, Barbara Dutz, Jan Kirchhof, Mark G. An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology |
title | An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology |
title_full | An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology |
title_fullStr | An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology |
title_full_unstemmed | An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology |
title_short | An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology |
title_sort | evidence-based guide to sars-cov-2 vaccination of patients on immunotherapies in dermatology |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816618/ https://www.ncbi.nlm.nih.gov/pubmed/33482251 http://dx.doi.org/10.1016/j.jaad.2021.01.047 |
work_keys_str_mv | AT greshamlouisem anevidencebasedguidetosarscov2vaccinationofpatientsonimmunotherapiesindermatology AT marzariobarbara anevidencebasedguidetosarscov2vaccinationofpatientsonimmunotherapiesindermatology AT dutzjan anevidencebasedguidetosarscov2vaccinationofpatientsonimmunotherapiesindermatology AT kirchhofmarkg anevidencebasedguidetosarscov2vaccinationofpatientsonimmunotherapiesindermatology AT greshamlouisem evidencebasedguidetosarscov2vaccinationofpatientsonimmunotherapiesindermatology AT marzariobarbara evidencebasedguidetosarscov2vaccinationofpatientsonimmunotherapiesindermatology AT dutzjan evidencebasedguidetosarscov2vaccinationofpatientsonimmunotherapiesindermatology AT kirchhofmarkg evidencebasedguidetosarscov2vaccinationofpatientsonimmunotherapiesindermatology |